Q4 2025 Gland Pharma Ltd Earnings Call Transcript
Key Points
- Gland Pharma Ltd (NSE:GLAND) is expanding its geographical presence into emerging markets such as Africa, the Middle East, Latin America, and Asia Pacific, which presents substantial market opportunities.
- The company has made significant progress in expanding its manufacturing capabilities, including the successful entry into the GLP-1 segment with the launch of Liraglutide.
- Gland Pharma Ltd (NSE:GLAND) has a robust R&D pipeline with 71 new NDAs targeting a $5.7 billion total addressable market, focusing on major therapies like ophthalmology, CNS, and cardiology.
- The company is experiencing significant momentum in attracting major pharmaceutical companies for high-value formats like dry powders, with several new CMO projects initiated.
- Gland Pharma Ltd (NSE:GLAND) is actively exploring inorganic opportunities via mergers and acquisitions to accelerate complex product development and expand its product range.
- The company faced near-term growth challenges, particularly due to reciprocal tariffs announced by the US administration, creating uncertainty for Indian pharmaceutical companies.
- Cenexi, a subsidiary of Gland Pharma Ltd (NSE:GLAND), has underperformed, with foundational groundwork for its turnaround in place but results falling short of expectations.
- The company's base business reported a 12% year-over-year decline in revenues for Q4 FY25, primarily due to higher marginal realization in the previous year and tender losses in RoW markets.
- Despite new product launches, the US business has been relatively flat, with revenue growth constrained by reduced material costs and end market prices.
- Cenexi's performance was impacted by lower production at the Fontenay facility due to ongoing remediation activities and equipment breakdowns, leading to reduced shipments and lower sales figures.
Ladies and gentlemen, good day and welcome to the Q4 FY25 earnings conference call of Gland Pharma Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Ms. Runjhun Jain. Thank you, and over to you, ma'am.
Thank you Sagar. Good evening, everyone. We welcome you to the Gland Pharma's earnings conference call for Q4 FY25. Today, we have Mr. Srinivas Sadu, Executive Chairperson; Mr. Shyamakant Giri, Chief Executive Officer; Mr. Ravi Mitra, Chief Financial Officer from India's Office; and Mr. Alain, CEO of Cenexi, who's connected virtually from France.
We will begin the call with business highlights from Mr. Sadu, followed by operational highlights of Mr. Giri. This will be taken by Mr. -- after Cenexi -- the update about Cenexi from Mr. Alain, and lastly, the group financial overview of Mr. Ravi.
Before we proceed, I would like to remind everyone that some of the statements made today will be forward-looking and are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
